Use of telocinobufagin as an analgesic in the treatment of acute and chronic pains
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Sep 24, 2013
Grant Date -
Mar 29, 2012
app pub date -
May 26, 2010
filing date -
May 28, 2009
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention is directed to the use of telocinobufagin, or its pharmaceutically acceptable derivatives, in the manufacture of a medicament for the treatment or prevention of acute and chronic pains. The present invention also refers to a pharmaceutical composition comprising an effective amount of telocinobufagin; also provides a method to induce analgesia in response to acute and chronic pains that comprehends administering an effective amount of telocinobufagin to human beings or animals. According to the outcomes of in vivo assays, telocinobufagin is more potent than morphine, though without presenting the known side effects of opioids. In addition, in vivo and in vitro essays showed that TBC does not present cardiotoxicity.
First Claim
Other Claims data not available
Family
International Classification(s)
- 2010 Application Filing Year
- A61K Class
- 10962 Applications Filed
- 7633 Patents Issued To-Date
- 69.64 % Issued To-Date
Cited Art Landscape
Patent Citation Ranking
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Mar 24, 2025 |
